The latest information about BioMark Diagnostics to keep you up to date.
BioMark Diagnostics is leading the world in early-stage cancer detection with an oncology focus designed to improve patient outcomes.
FORM 7MONTHLY PROGRESS REPORT Name of Listed Issuer: BioMark Diagnostics Inc. _____ (the
BIOMARK TO PRESENT NEW CANCER SCREENING DATA USING THE LDTD-MS/MS TECHNIQUE AT THE ANNUAL ASMS
FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed
Vancouver, British Columbia – (June 29th, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE:
Vancouver, British Columbia – (June 1st, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE:
Vancouver, Colombie-Britannique – (1er juin 2021) – BioMark Diagnostics Inc. («BioMark») (CSE: BUX) (FSE: 20B)
Vancouver, British Columbia – (May 31, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE:
Vancouver, British Columbia – (April 29, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE:
Vancouver, British Columbia – (April 21, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE:
No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2
Rashid A. Bux (CEO)
[email protected]